Always a price to be paid for long term immunosuppression

Gilenya, or Fingolimod, is the first approved oral disease modifying drug for MS.
Post Reply
Cliffhanger
Newbie
Posts: 6
Joined: Fri May 20, 2016 11:14 am

Always a price to be paid for long term immunosuppression

Post by Cliffhanger » Fri Jun 03, 2016 9:29 am

I so wish that a new MS drug, preferably oral, without immunosuppression features would eventually be developed ... because we really need it.

There is always a price to be paid for long term immunosuppression.

So this is what I read today in a newly published paper - and it relates to all drugs that have immunosuppression as a charactersitica:

" AIDS-related cancer seen in someone treated with Fingolimod (Brand name: Gilenya) . This case highlights potential risks associated with immunosuppression with this medicine and ongoing need for vigilance in assessing for such complications. "

Source:
http://multiple-sclerosis-research.blog ... meone.html


Also ... I want to add ... risk of PML is well linked to all drugs that act via heavily immunosuppression. Especially in long term.


TO SUM UP:
SO, when will we see a drug that does not have clear immunosuppressive features, that is fairly efficient and low risks ...(?) I think we all long for such drug.

Post Reply
  • Similar Topics
    Replies
    Views
    Last post